AUROPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.4
| Stock Code | AUROPHARMA | Market Cap | 72,455 Cr. | Current Price | 1,248 ₹ | High / Low | 1,320 ₹ |
| Stock P/E | 33.8 | Book Value | 369 ₹ | Dividend Yield | 0.32 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,213 ₹ | DMA 200 | 1,177 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 53.2 | MACD | 26.0 | Volume | 8,45,543 | Avg Vol 1Wk | 12,77,838 |
| Low price | 994 ₹ | High price | 1,320 ₹ | PEG Ratio | 7.92 | Debt to equity | 0.21 |
| 52w Index | 77.8 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 27.2 |
📊 The stock AUROPHARMA shows moderate potential for swing trading. Current price (₹1,248) is above both 50 DMA (₹1,213) and 200 DMA (₹1,177), indicating bullish technicals. RSI at 53.2 is neutral, while MACD is positive (26.0), suggesting upward momentum. Valuation is slightly stretched with P/E of 33.8 compared to industry average of 27.2, and PEG ratio of 7.92 indicates overvaluation relative to growth. Volume is below weekly average, showing weaker participation despite recent gains.
💡 Optimal Entry Price: Around ₹1,220–1,230 if price consolidates near support.
📉 Exit Strategy (if already holding): Consider exiting near ₹1,300–1,320 resistance zone unless strong breakout occurs.
✅ Positive
- Quarterly PAT improved from ₹581 Cr. to ₹595 Cr.
- EPS of ₹36.7 shows consistent earnings power.
- Dividend yield of 0.32% provides minor investor return.
⚠️ Limitation
- ROCE (10.8%) and ROE (8.65%) are modest compared to peers.
- PEG ratio (7.92) suggests overvaluation relative to growth.
- Trading volume below weekly average, limiting momentum strength.
📉 Company Negative News
- FII holding decreased (-0.26%), showing reduced foreign investor confidence.
📈 Company Positive News
- DII holding increased (+0.06%), showing domestic institutional support.
- Quarterly profit variance (+26.0%) indicates improving performance.
🏭 Industry
- Industry P/E at 27.2 shows peers trade at lower valuations.
- Pharmaceutical sector remains stable with long-term growth potential.
🔎 Conclusion
AUROPHARMA shows bullish technical signals but is moderately overvalued compared to industry peers. It can be considered for swing trading with entry near ₹1,220–1,230 and exit near ₹1,300–1,320. Caution is advised due to stretched valuations and weaker trading volume.